AccuCinch Demonstrates Sustained Cardiac Reverse Remodeling Through Two Years in Patients with HFrEF

Ancora HeartIn progressPublished in "Structural Heart》Release ConcernFor its left ventricular repair device---AccuCinchTwo-year clinical research data. The study showsAccuCinchThe cardiac reverse remodeling effect achieved can be maintained for two years, accompanied by improved heart function, enhanced quality of life, and a reduced rate of heart failure hospitalizations.

Specific Research DataAccording to (51 patients with symptomatic HFrEF）

• Achieving sustained reverse remodeling: Left ventricular end-diastolic volume decreased by an average of 30.0±38.8 mL (p<0.001), and ejection fraction increased by an average of 5.4±9.0% (p<0.001).

• Functional Status and Symptom Improvement: The median increase in Kansas City Cardiomyopathy Questionnaire score was 19.5 points (p<0.001), with 60% of patients experiencing at least one grade improvement in NYHA functional class, and 98% of patients showing improvement or stable condition.

• The rate of heart failure hospitalization two years after implantation was significantly lower than that one year before the procedure (p<0.001).

PI Evaluation

"Reverse cardiac remodeling is typically associated with a reduction in heart failure events and mortality; clinically, the maintenance of reverse remodeling effects for two years is particularly noteworthy."

---Daniel Burkhoff

Executive Evaluation

"Two-year data further confirm that AccuCinch has the potential to achieve sustained and effective reverse cardiac remodeling. We are advancing this research through the pivotal CORCINCH-HF trial to evaluate the safety and efficacy of AccuCinch. The first 250 enrolled patients are nearing completion of their six-month follow-up assessment, and these data will serve as a critical component of the pre-market approval application, marking a key step forward in our efforts to promote this therapy."

---Jeff Closs  President and CEO of Ancora Heart

Approximately 6.7 million adults in the U.S. suffer from heart failure (HF) at varying degrees, which leads to weakened myocardial function and reduced ability to pump oxygen-rich blood. Patients often experience persistent fatigue, shortness of breath, confusion, and other debilitating symptoms, with frequent hospitalizations. About half of HF patients exhibit heart failure with reduced ejection fraction (HFrEF) accompanied by left ventricular enlargement, resulting in increased cardiac load and decreased pumping efficiency. Nearly 50% of HF patients die within five years of diagnosis.

Ancora HeartDevelopmentAccuCinchAddress the current issue of untreatable heart failure, despiteAccuCinchHeart failure cannot be cured, but its progression can be delayed while improving the patient's quality of life.AccuCinchThe preliminary results have been confirmed in early clinical studies. ThereforeAncora HeartLaunch a larger-scale clinical studyStudy (CORCINCH-HF), this study plans to enroll 400 patients, and has currently reached the milestone of the first round of 250 randomized enrollments. The six-month follow-up data from this cohort will supportAncora HeartSubmit a Pre-Market Approval Application to the U.S. FDA.

AccuCinchIt is currently the only device for treating heart failure that can achieve the following functions:

• Reduce Left Ventricular Dimensions
• Reduce Left Ventricular Volume
• Directly support the left ventricular wall
• Reduce Mitral Valve Prolapse

Advantages of AccuCinch

• Directly targets left ventricular dysfunction and dilation

• Through the percutaneous retrograde femoral artery approach, rather than via the atrial septum or apex.

• Preservation of the natural mitral valve structure

• Preserve All Future Treatment Options

AccuCinchPrinciple of Treatment

Principle Comparison

AccuCinch Left Ventricular Repair

AccuCinchIt is a flexible implant that allows fixation to the inner wall of the left ventricle.AccuCinchThe purpose is to reduce the size of the left ventricle, decrease ventricular wall stress, and support and strengthen the heart wall.

Ancora Heart